Kirsten brings more than 25 years of extensive commercial, development, and strategic leadership experience from both large pharmaceutical and smaller biotech organizations.

Prior to co-founding and becoming CEO of Chiara Biosciences, Kirsten was the Chief Commercial & Corporate Strategy officer for Kura Oncology (Nasdaq: KURA) for just over three years developing the pipeline, commercial, and medical affairs strategy for Kura and hiring the first executives for these functions. Prior to her tenure at Kura, Kirsten served as the Sr. Vice-President of Commercial Operations at Array Biopharma where she built and led the commercial organization that delivered the successful launch of Braftovi® + Mektovi® ultimately resulting in an $11.4 billion company acquisition by Pfizer. Before joining Array, she held several ascending leadership positions within Pfizer including the U.S. commercial lead for the launch of the blockbuster drugs IBRANCE® in breast cancer and INLYTA® in renal cell carcinoma, and roles in Pipeline Strategy for Specialty Care (including Inflammation, Oncology, Opthalmology, and Rare Disease). Kirsten also serves on the Board for PMV Pharmaceuticals, Inc. (Nasdaq: PMVP).

Kirsten earned her MBA from Harvard Business School, and her BS in Molecular & Cellular Biology and Psychology from the University of Arizona.